{"id":29089,"date":"2025-02-06T02:02:59","date_gmt":"2025-02-06T02:02:59","guid":{"rendered":"https:\/\/quantfury.com\/?p=29089"},"modified":"2025-07-25T18:54:14","modified_gmt":"2025-07-25T18:54:14","slug":"vertex","status":"publish","type":"post","link":"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/","title":{"rendered":"O analg\u00e9sico n\u00e3o opioide da Vertex pode ser um divisor de \u00e1guas"},"content":{"rendered":"\n<p>As a\u00e7\u00f5es da Vertex Pharmaceuticals (<a href=\"https:\/\/trading.quantfury.com\/chart_full?shortName=VRTX\">NASDAQ: VRTX<\/a>) est\u00e3o em alta em meio ao entusiasmo por seu analg\u00e9sico n\u00e3o-opioide Journavx.<\/p>\n\n\n\n<p>As a\u00e7\u00f5es aumentaram 18% no m\u00eas passado somente pela mera expectativa da aprova\u00e7\u00e3o regulat\u00f3ria do medicamento. Essa aprova\u00e7\u00e3o foi dada pelo \u00f3rg\u00e3o regulador FDA (Food and Drug Administration) dos EUA na semana passada. Journavx \u00e9 o primeiro novo analg\u00e9sico n\u00e3o-opioide aprovado nos EUA em mais de 20 anos.<\/p>\n\n\n\n<p>A droga tem um enorme potencial, dizem os especialistas. O mercado global de dor cr\u00f4nica totalizou US$ 72,1 bilh\u00f5es no ano passado, de acordo com estimativas da Coherent Market Insights. A Precedence Research estimou que os opioides representaram US$ 23,1 bilh\u00f5es desse valor, o equivalente a 32% do total.<\/p>\n\n\n\n<p>Os opioides limitam a dor aderindo a receptores no c\u00e9rebro que atraem sinais nervosos de diferentes partes do corpo. Esse processo no c\u00e9rebro desencadeia os efeitos viciantes dos opioides. E os opioides &#8211; como Oxycontin, Vicodin e Percocet &#8211; podem ter efeitos colaterais severos, incluindo tontura e lentid\u00e3o.<\/p>\n\n\n\n<p>Journavx, por outro lado, n\u00e3o consegue entrar no c\u00e9rebro. Ele repele prote\u00ednas que geram sinais de dor que viajam para o c\u00e9rebro, ao contr\u00e1rio dos opioides.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-as-vendas-podem-crescer-rapidamente\">As vendas podem crescer rapidamente<\/h2>\n\n\n\n<p><\/p>\n\n\n\n<p>Os analistas de Wall Street preveem que o Journavx obter\u00e1 US$ 100 milh\u00f5es em vendas este ano, alcan\u00e7ando US$ 1 bilh\u00e3o em 2028, de acordo com a FactSet. Isso representaria cerca de 10% da receita da Vertex em 2023.<\/p>\n\n\n\n<p>O carro-chefe da empresa s\u00e3o os medicamentos para fibrose c\u00edstica. Quase 50% dos pacientes em todo o mundo que recebem tratamento para a doen\u00e7a utilizam medicamentos da Vertex. A empresa est\u00e1 tentando aumentar seu portf\u00f3lio de medicamentos, e \u00e9 a\u00ed que entra o Journavx.<\/p>\n\n\n\n<p>Obviamente, existem alguns obst\u00e1culos para a droga. O Journavx \u00e9 caro, custando US$ 15,50 por comprimido, quando comparado com o Vicodin e o Oxycontin, que custam aproximadamente entre US$ 1,40 e US$ 1,50. Esses valores podem desencorajar as seguradoras de cobrir o novo tratamento, e os hospitais ainda podem preferir prescrever opioides.<\/p>\n\n\n\n<p>Al\u00e9m disso, os testes de Journavx da Vertex levantaram algumas quest\u00f5es. Um estudo mostrou que o Journavx n\u00e3o foi mais eficaz do que um placebo no combate \u00e0 dor lombar.<\/p>\n\n\n\n<p>A droga tamb\u00e9m n\u00e3o acabar\u00e1 com o flagelo dos opioides que matou 81.000 pessoas em 2023, de acordo com dados dos Centros de Controle e Preven\u00e7\u00e3o de Doen\u00e7as. Isso porque a morte dessas pessoas foi causada principalmente pelo fentanil, e n\u00e3o por opioides prescritos.<\/p>\n\n\n\n<p>Ainda assim, apesar dessas limita\u00e7\u00f5es, o Journavx tem um grande potencial.<\/p>\n\n\n\n<p><em>Nota: O autor possui a\u00e7\u00f5es da Vertex.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>As a\u00e7\u00f5es da Vertex Pharmaceuticals (NASDAQ: VRTX) est\u00e3o em alta em meio ao entusiasmo por seu analg\u00e9sico n\u00e3o-opioide Journavx. As a\u00e7\u00f5es aumentaram 18% no m\u00eas passado somente pela mera expectativa da aprova\u00e7\u00e3o regulat\u00f3ria do medicamento. Essa aprova\u00e7\u00e3o foi dada pelo \u00f3rg\u00e3o regulador FDA (Food and Drug Administration) dos EUA na semana passada. Journavx \u00e9 o [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[733,9],"tags":[],"class_list":["post-29089","post","type-post","status-publish","format-standard","hentry","category-acoes-em-foco","category-insights-do-mercado"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>O analg\u00e9sico n\u00e3o opioide da Vertex pode ser um divisor de \u00e1guas | Quantfury<\/title>\n<meta name=\"description\" content=\"As a\u00e7\u00f5es da Vertex Pharmaceuticals (NASDAQ: VRTX) est\u00e3o em alta em meio ao entusiasmo por seu analg\u00e9sico n\u00e3o-opioide Journavx.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"O analg\u00e9sico n\u00e3o opioide da Vertex pode ser um divisor de \u00e1guas | Quantfury\" \/>\n<meta property=\"og:description\" content=\"As a\u00e7\u00f5es da Vertex Pharmaceuticals (NASDAQ: VRTX) est\u00e3o em alta em meio ao entusiasmo por seu analg\u00e9sico n\u00e3o-opioide Journavx.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/\" \/>\n<meta property=\"og:site_name\" content=\"Quantfury\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-06T02:02:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-25T18:54:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/quantfury.com\/wp-content\/uploads\/2025\/02\/Vertex.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"1536\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Quantfury\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"As a\u00e7\u00f5es da Vertex Pharmaceuticals (NASDAQ: VRTX) est\u00e3o em alta em meio ao entusiasmo por seu analg\u00e9sico n\u00e3o-opioide Journavx. As a\u00e7\u00f5es aumentaram 18% no\" \/>\n<meta name=\"twitter:creator\" content=\"@quantfury\" \/>\n<meta name=\"twitter:site\" content=\"@quantfury\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Quantfury\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/\"},\"author\":{\"name\":\"Quantfury\",\"@id\":\"https:\/\/quantfury.com\/#\/schema\/person\/a9f7e8493050fd0144e9482425234990\"},\"headline\":\"O analg\u00e9sico n\u00e3o opioide da Vertex pode ser um divisor de \u00e1guas\",\"datePublished\":\"2025-02-06T02:02:59+00:00\",\"dateModified\":\"2025-07-25T18:54:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/\"},\"wordCount\":457,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/quantfury.com\/#organization\"},\"articleSection\":[\"A\u00e7\u00f5es em foco\",\"Insights do Mercado\"],\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/\",\"url\":\"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/\",\"name\":\"O analg\u00e9sico n\u00e3o opioide da Vertex pode ser um divisor de \u00e1guas | Quantfury\",\"isPartOf\":{\"@id\":\"https:\/\/quantfury.com\/#website\"},\"datePublished\":\"2025-02-06T02:02:59+00:00\",\"dateModified\":\"2025-07-25T18:54:14+00:00\",\"description\":\"As a\u00e7\u00f5es da Vertex Pharmaceuticals (NASDAQ: VRTX) est\u00e3o em alta em meio ao entusiasmo por seu analg\u00e9sico n\u00e3o-opioide Journavx.\",\"breadcrumb\":{\"@id\":\"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/quantfury.com\/portuge\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"O analg\u00e9sico n\u00e3o opioide da Vertex pode ser um divisor de \u00e1guas\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/quantfury.com\/#website\",\"url\":\"https:\/\/quantfury.com\/\",\"name\":\"Quantfury\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/quantfury.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/quantfury.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/quantfury.com\/#organization\",\"name\":\"Quantfury\",\"url\":\"https:\/\/quantfury.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\/\/quantfury.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/quantfury.com\/wp-content\/uploads\/2021\/04\/logo.svg\",\"contentUrl\":\"https:\/\/quantfury.com\/wp-content\/uploads\/2021\/04\/logo.svg\",\"width\":165,\"height\":36,\"caption\":\"Quantfury\"},\"image\":{\"@id\":\"https:\/\/quantfury.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/quantfury\",\"https:\/\/instagram.com\/quantfury\",\"https:\/\/www.linkedin.com\/company\/quantfury\/\",\"https:\/\/www.youtube.com\/c\/Quantfury\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/quantfury.com\/#\/schema\/person\/a9f7e8493050fd0144e9482425234990\",\"name\":\"Quantfury\",\"sameAs\":[\"https:\/\/quantfury.com\"],\"url\":\"https:\/\/quantfury.com\/portuge\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"O analg\u00e9sico n\u00e3o opioide da Vertex pode ser um divisor de \u00e1guas | Quantfury","description":"As a\u00e7\u00f5es da Vertex Pharmaceuticals (NASDAQ: VRTX) est\u00e3o em alta em meio ao entusiasmo por seu analg\u00e9sico n\u00e3o-opioide Journavx.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/","og_locale":"pt_PT","og_type":"article","og_title":"O analg\u00e9sico n\u00e3o opioide da Vertex pode ser um divisor de \u00e1guas | Quantfury","og_description":"As a\u00e7\u00f5es da Vertex Pharmaceuticals (NASDAQ: VRTX) est\u00e3o em alta em meio ao entusiasmo por seu analg\u00e9sico n\u00e3o-opioide Journavx.","og_url":"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/","og_site_name":"Quantfury","article_published_time":"2025-02-06T02:02:59+00:00","article_modified_time":"2025-07-25T18:54:14+00:00","og_image":[{"width":2048,"height":1536,"url":"https:\/\/quantfury.com\/wp-content\/uploads\/2025\/02\/Vertex.jpg","type":"image\/jpeg"}],"author":"Quantfury","twitter_card":"summary_large_image","twitter_description":"As a\u00e7\u00f5es da Vertex Pharmaceuticals (NASDAQ: VRTX) est\u00e3o em alta em meio ao entusiasmo por seu analg\u00e9sico n\u00e3o-opioide Journavx. As a\u00e7\u00f5es aumentaram 18% no","twitter_creator":"@quantfury","twitter_site":"@quantfury","twitter_misc":{"Escrito por":"Quantfury","Tempo estimado de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/#article","isPartOf":{"@id":"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/"},"author":{"name":"Quantfury","@id":"https:\/\/quantfury.com\/#\/schema\/person\/a9f7e8493050fd0144e9482425234990"},"headline":"O analg\u00e9sico n\u00e3o opioide da Vertex pode ser um divisor de \u00e1guas","datePublished":"2025-02-06T02:02:59+00:00","dateModified":"2025-07-25T18:54:14+00:00","mainEntityOfPage":{"@id":"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/"},"wordCount":457,"commentCount":0,"publisher":{"@id":"https:\/\/quantfury.com\/#organization"},"articleSection":["A\u00e7\u00f5es em foco","Insights do Mercado"],"inLanguage":"pt-PT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/","url":"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/","name":"O analg\u00e9sico n\u00e3o opioide da Vertex pode ser um divisor de \u00e1guas | Quantfury","isPartOf":{"@id":"https:\/\/quantfury.com\/#website"},"datePublished":"2025-02-06T02:02:59+00:00","dateModified":"2025-07-25T18:54:14+00:00","description":"As a\u00e7\u00f5es da Vertex Pharmaceuticals (NASDAQ: VRTX) est\u00e3o em alta em meio ao entusiasmo por seu analg\u00e9sico n\u00e3o-opioide Journavx.","breadcrumb":{"@id":"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/quantfury.com\/portuge\/insights-do-mercado\/vertex\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/quantfury.com\/portuge\/"},{"@type":"ListItem","position":2,"name":"O analg\u00e9sico n\u00e3o opioide da Vertex pode ser um divisor de \u00e1guas"}]},{"@type":"WebSite","@id":"https:\/\/quantfury.com\/#website","url":"https:\/\/quantfury.com\/","name":"Quantfury","description":"","publisher":{"@id":"https:\/\/quantfury.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/quantfury.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Organization","@id":"https:\/\/quantfury.com\/#organization","name":"Quantfury","url":"https:\/\/quantfury.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/quantfury.com\/#\/schema\/logo\/image\/","url":"https:\/\/quantfury.com\/wp-content\/uploads\/2021\/04\/logo.svg","contentUrl":"https:\/\/quantfury.com\/wp-content\/uploads\/2021\/04\/logo.svg","width":165,"height":36,"caption":"Quantfury"},"image":{"@id":"https:\/\/quantfury.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/quantfury","https:\/\/instagram.com\/quantfury","https:\/\/www.linkedin.com\/company\/quantfury\/","https:\/\/www.youtube.com\/c\/Quantfury"]},{"@type":"Person","@id":"https:\/\/quantfury.com\/#\/schema\/person\/a9f7e8493050fd0144e9482425234990","name":"Quantfury","sameAs":["https:\/\/quantfury.com"],"url":"https:\/\/quantfury.com\/portuge\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/quantfury.com\/portuge\/wp-json\/wp\/v2\/posts\/29089","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quantfury.com\/portuge\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quantfury.com\/portuge\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quantfury.com\/portuge\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quantfury.com\/portuge\/wp-json\/wp\/v2\/comments?post=29089"}],"version-history":[{"count":3,"href":"https:\/\/quantfury.com\/portuge\/wp-json\/wp\/v2\/posts\/29089\/revisions"}],"predecessor-version":[{"id":35096,"href":"https:\/\/quantfury.com\/portuge\/wp-json\/wp\/v2\/posts\/29089\/revisions\/35096"}],"wp:attachment":[{"href":"https:\/\/quantfury.com\/portuge\/wp-json\/wp\/v2\/media?parent=29089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quantfury.com\/portuge\/wp-json\/wp\/v2\/categories?post=29089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quantfury.com\/portuge\/wp-json\/wp\/v2\/tags?post=29089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}